Since the birth of the first ‘test tube baby’, Louise Brown, in 1978, around four million babies have been born following IVF, many as a result of the ICSI technique, which today accounts for over 60% of all IVF treatments. ICSI was first used at the beginning of the nineties and in 1996, Eppendorf launched the electronic micromanipulator TransferMan®. Demand for IVF treatments continues to grow and Eppendorf remains at the forefront of product development in this area. Today the micromanipulator TransferMan® NK 2 and the microinjectors of the CellTram® series offer the highest precision for all common applications such as ICSI, IMSI, TESE, assisted hatching and polar body biopsy. For these techniques, certified, sterile, high precision microcapillaries are also available. Eppendorf VacuTip® and TransferTip®, as well as Polar Body Biopsy Tip MML and IMSI/TESE Tip microcapillaries are certified for use in IVF laboratories.
Designed to meet the specific demands of these highly specialised IVF techniques and subjected to intensive quality control, Eppendorf microcapillaries ensure reproducible quality and sterility.
Eppendorf UK, incorporating New Brunswick from 1st January 2011, is headquartered in Cambridge and a subsidiary of Eppendorf AG, Hamburg, Germany. With over 2,500 employees on four continents, Eppendorf AG is a leading global supplier of systems and research tools for the biotechnology industry. The company achieved a turnover of £368m (€433m) in 2009 and operating profits (EBIT) of £61.4m (€72.2m).
This information is now due for UK release. www.eppendorf.co.uk